There’s currently no reliable screening test for ovarian cancer, meaning that most cases are caught at an advanced stage, ...

You might hear about your risk of ovarian cancer through an aunt, mother, sister or grandmother. For some, there are no signs of hereditary cancer in the family, but genetic testing still reveals a ...

Is the Galleri multi-cancer blood test worth it? A doctor's analyses of real-world performance data. Learn why no major ...

A new ovarian cancer surveillance test is now being offered to women with an inherited risk of the disease, marking a significant development in care. University College London Hospitals NHS ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...

Removing the fallopian tubes during routine gynecological surgery reduced the risk of serous ovarian cancer by nearly 80%.

Ovarian cancer kills more women than any other gynecological cancer. Most patients receive their diagnosis only after the ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian ...

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.

Ovarian cancer spreads fast by recruiting the body’s own protective cells to clear the way—and that secret alliance may finally be its undoing.

Sept. 12 -- FRIDAY, Sept. 11 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new test for women with pelvic tumors that are known to need surgery. The test, called OVA1, will ...